Almost one-third of Americans currently take antidepressant medications. Despite the number of antidepressants available, up to 30% of patients do not respond to their first antidepressant medication.
Virtually all medications used to treat depression are metabolized by two enzymes in the liver: CYP2D6 and CYP2C19. Other metabolic pathways include CYP1A2, CYP2B6, and CYP3A4.
Your genes are the main factor in determining the level of these enzymes in your liver and other organs. If you have too much of the enzyme, you process the medication too quickly, too little of the enzyme and the medication builds up in your bloodstream potentially causing adverse reactions or side effects. Without knowing your genetics, your physician may need to go through months of trial-and-error
PGx AND DEPRESSION
Learn How Depression, Genes, and Drugs Work Together
Over the last decade, significant advancements in pharmacogenetics or “personalized medicine” have provided alternative methods for selecting drugs based on a patient's unique genetic profiles.
Pharmacogenetic testing complements current efforts to optimize personalized care in depression patients — all while being more cost effective and reducing trial-and-error efforts.
Population Frequency of Cytochrome P450 Metabolizer Types 
|Poor (no or low enzyme levels)||Intermediate (reduced enzyme levels)||normal (normal enzyme levels)||Rapid or Ultra Rapid (high enzyme levels)|
*CYP2C19 variability depends on ethnicity.
*CYP2D6 Variability depends on ethnicity and classification of Intermediate activity
Additional psychiatric medications that are impacted by your genetics: